{"id":67071,"date":"2026-06-02T13:29:01","date_gmt":"2026-06-02T05:29:01","guid":{"rendered":"https:\/\/flcube.com\/?p=67071"},"modified":"2026-06-02T13:29:01","modified_gmt":"2026-06-02T05:29:01","slug":"livzon-pharmaceutical-secures-nmpa-approval-for-lzm012-xkh004-chinas-first-il-17a-f-dual-inhibitor-for-ankylosing-spondylitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67071","title":{"rendered":"Livzon Pharmaceutical Secures NMPA Approval for LZM012\/XKH004, China&#8217;s First IL-17A\/F Dual Inhibitor for Ankylosing Spondylitis"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Livzon Pharmaceutical Group Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1513:HKG\">HKG: 1513<\/a>) announced it has received <strong>marketing approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>LZM012\/XKH004<\/strong>, its <strong>Category 1 biologic product<\/strong> and <strong>IL-17A\/F dual target inhibitor<\/strong>, for the treatment of patients with <strong>active ankylosing spondylitis (AS)<\/strong> who have had an inadequate response to or are intolerant of conventional therapy.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-product-details\" class=\"wp-block-heading\">Regulatory Milestone &amp; Product Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Livzon Pharmaceutical Group Inc. (HKG: 1513)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>LZM012\/XKH004 \u2013 Category 1 biologic<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>IL-17A\/F dual target inhibitor<\/td><\/tr><tr><td><strong>Approval Agency<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Active ankylosing spondylitis (radiographic axial spondyloarthritis)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Inadequate responders or intolerant to conventional therapy<\/td><\/tr><tr><td><strong>Additional Indications<\/strong><\/td><td>Under marketing review for moderate-to-severe plaque psoriasis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-iii-trial-results\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase III Trial Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><th>Duration<\/th><\/tr><\/thead><tbody><tr><td><strong>Inflammatory Marker Improvement<\/strong><\/td><td>Rapid reduction in CRP and ESR levels<\/td><td>Early timepoints<\/td><\/tr><tr><td><strong>Efficacy Sustainability<\/strong><\/td><td>Sustained clinical benefit maintained<\/td><td><strong>52 weeks<\/strong><\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Overall safe and well-tolerated<\/td><td>Throughout study period<\/td><\/tr><tr><td><strong>Primary Endpoints<\/strong><\/td><td>Met with statistical significance<\/td><td>Not specified in release<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The Phase III clinical program demonstrated that LZM012\/XKH004 provides rapid and sustained improvement in disease activity for AS patients, addressing a significant unmet medical need in China&#8217;s growing autoimmune disease market.<\/p>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> Dual inhibition of IL-17A and IL-17F cytokines<\/li>\n\n\n\n<li><strong>Rationale:<\/strong> Simultaneous blockade of both key inflammatory mediators in the IL-17 pathway<\/li>\n\n\n\n<li><strong>Advantage:<\/strong> Potentially superior efficacy compared to selective IL-17A inhibitors by comprehensively targeting the pathway<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First IL-17A\/F dual inhibitor approved in China for ankylosing spondylitis<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Category 1 biologic designation indicates novel molecular entity developed domestically<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>AS Prevalence in China<\/strong><\/td><td>Estimated 4-5 million AS patients; significant undertreated population<\/td><\/tr><tr><td><strong>Current Treatment Options<\/strong><\/td><td>TNF inhibitors dominate market; limited IL-17 inhibitor availability<\/td><\/tr><tr><td><strong>Global IL-17 Inhibitors<\/strong><\/td><td>Cosentyx (secukinumab), Taltz (ixekizumab), Bimzelx (bimekizumab) established internationally<\/td><\/tr><tr><td><strong>Livzon&#8217;s Competitive Edge<\/strong><\/td><td>First-mover advantage as domestic developer with NMPA priority review<\/td><\/tr><tr><td><strong>Market Opportunity<\/strong><\/td><td>Chinese AS biologics market projected to reach \u00a58.5 billion ($1.2 billion) by 2030<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-amp-commercial-outlook\" class=\"wp-block-heading\">Strategic Implications &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Domestic Innovation Leadership:<\/strong> Reinforces Livzon&#8217;s position as leading Chinese biopharmaceutical innovator<\/li>\n\n\n\n<li><strong>Dual-Indication Strategy:<\/strong> Psoriasis approval would significantly expand addressable market<\/li>\n\n\n\n<li><strong>Pricing Advantage:<\/strong> Domestic manufacturing and development may enable competitive pricing versus imported biologics<\/li>\n\n\n\n<li><strong>Reimbursement Potential:<\/strong> Category 1 biologic status supports inclusion in national reimbursement drug list (NRDL)<\/li>\n\n\n\n<li><strong>Export Potential:<\/strong> Success in China could facilitate regulatory filings in other emerging markets<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The NMPA approval marks a significant milestone for Livzon, establishing LZM012\/XKH004 as China&#8217;s first domestically developed IL-17A\/F dual inhibitor and potentially reshaping the AS treatment landscape in the world&#8217;s second-largest pharmaceutical market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical outcomes, and commercial expectations for LZM012\/XKH004. Actual results may differ due to risks including market adoption, reimbursement decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060103885_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026060103885_c.\"><\/object><a id=\"wp-block-file--media-9b7bfa2b-14f0-40a3-a9dd-b1efbba07506\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060103885_c.pdf\">2026060103885_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060103885_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9b7bfa2b-14f0-40a3-a9dd-b1efbba07506\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Livzon Pharmaceutical Group Inc. (HKG: 1513) announced it has received marketing approval from China&#8217;s National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1228,457,38],"class_list":["post-67071","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-hkg-1513","tag-livzon-pharmaceutical","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Livzon Pharmaceutical Secures NMPA Approval for LZM012\/XKH004, China&#039;s First IL-17A\/F Dual Inhibitor for Ankylosing Spondylitis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Livzon Pharmaceutical Group Inc. (HKG: 1513) announced it has received marketing approval from China&#039;s National Medical Products Administration (NMPA) for LZM012\/XKH004, its Category 1 biologic product and IL-17A\/F dual target inhibitor, for the treatment of patients with active ankylosing spondylitis (AS) who have had an inadequate response to or are intolerant of conventional therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67071\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Livzon Pharmaceutical Secures NMPA Approval for LZM012\/XKH004, China&#039;s First IL-17A\/F Dual Inhibitor for Ankylosing Spondylitis\" \/>\n<meta property=\"og:description\" content=\"Livzon Pharmaceutical Group Inc. (HKG: 1513) announced it has received marketing approval from China&#039;s National Medical Products Administration (NMPA) for LZM012\/XKH004, its Category 1 biologic product and IL-17A\/F dual target inhibitor, for the treatment of patients with active ankylosing spondylitis (AS) who have had an inadequate response to or are intolerant of conventional therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67071\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-02T05:29:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67071#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67071\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Livzon Pharmaceutical Secures NMPA Approval for LZM012\\\/XKH004, China&#8217;s First IL-17A\\\/F Dual Inhibitor for Ankylosing Spondylitis\",\"datePublished\":\"2026-06-02T05:29:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67071\"},\"wordCount\":488,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 1513\",\"Livzon Pharmaceutical\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67071#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67071\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67071\",\"name\":\"Livzon Pharmaceutical Secures NMPA Approval for LZM012\\\/XKH004, China's First IL-17A\\\/F Dual Inhibitor for Ankylosing Spondylitis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-02T05:29:01+00:00\",\"description\":\"Livzon Pharmaceutical Group Inc. (HKG: 1513) announced it has received marketing approval from China's National Medical Products Administration (NMPA) for LZM012\\\/XKH004, its Category 1 biologic product and IL-17A\\\/F dual target inhibitor, for the treatment of patients with active ankylosing spondylitis (AS) who have had an inadequate response to or are intolerant of conventional therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67071#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67071\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67071#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Livzon Pharmaceutical Secures NMPA Approval for LZM012\\\/XKH004, China&#8217;s First IL-17A\\\/F Dual Inhibitor for Ankylosing Spondylitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Livzon Pharmaceutical Secures NMPA Approval for LZM012\/XKH004, China's First IL-17A\/F Dual Inhibitor for Ankylosing Spondylitis - Insight, China&#039;s Pharmaceutical Industry","description":"Livzon Pharmaceutical Group Inc. (HKG: 1513) announced it has received marketing approval from China's National Medical Products Administration (NMPA) for LZM012\/XKH004, its Category 1 biologic product and IL-17A\/F dual target inhibitor, for the treatment of patients with active ankylosing spondylitis (AS) who have had an inadequate response to or are intolerant of conventional therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67071","og_locale":"en_US","og_type":"article","og_title":"Livzon Pharmaceutical Secures NMPA Approval for LZM012\/XKH004, China's First IL-17A\/F Dual Inhibitor for Ankylosing Spondylitis","og_description":"Livzon Pharmaceutical Group Inc. (HKG: 1513) announced it has received marketing approval from China's National Medical Products Administration (NMPA) for LZM012\/XKH004, its Category 1 biologic product and IL-17A\/F dual target inhibitor, for the treatment of patients with active ankylosing spondylitis (AS) who have had an inadequate response to or are intolerant of conventional therapy.","og_url":"https:\/\/flcube.com\/?p=67071","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-02T05:29:01+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67071#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67071"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Livzon Pharmaceutical Secures NMPA Approval for LZM012\/XKH004, China&#8217;s First IL-17A\/F Dual Inhibitor for Ankylosing Spondylitis","datePublished":"2026-06-02T05:29:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67071"},"wordCount":488,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 1513","Livzon Pharmaceutical","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67071#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67071","url":"https:\/\/flcube.com\/?p=67071","name":"Livzon Pharmaceutical Secures NMPA Approval for LZM012\/XKH004, China's First IL-17A\/F Dual Inhibitor for Ankylosing Spondylitis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-02T05:29:01+00:00","description":"Livzon Pharmaceutical Group Inc. (HKG: 1513) announced it has received marketing approval from China's National Medical Products Administration (NMPA) for LZM012\/XKH004, its Category 1 biologic product and IL-17A\/F dual target inhibitor, for the treatment of patients with active ankylosing spondylitis (AS) who have had an inadequate response to or are intolerant of conventional therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67071#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67071"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67071#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Livzon Pharmaceutical Secures NMPA Approval for LZM012\/XKH004, China&#8217;s First IL-17A\/F Dual Inhibitor for Ankylosing Spondylitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67071"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67071\/revisions"}],"predecessor-version":[{"id":67073,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67071\/revisions\/67073"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}